Association of IL27 gene polymorphisms and HBV-related hepatocellular carcinoma risk in a Chinese population

Infection, Genetics and Evolution

Volumn 16, Issue , 2013, Pages 1-4

  Peng, Qiliu ^a   Qin, Xue ^a   He, Yani ^a,b   Chen, Zhiping ^c   Deng, Yan ^a   Li, Taijie ^a   Xie, Li ^a   Zhao, Jinmin ^a   Li, Shan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b No1 People's Hospital of Nanning   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Hepatocellular carcinoma; Interleukin 27; Liver cirrhosis; Polymorphism

Indexed keywords

INTERLEUKIN 27;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERLEUKIN 27 GENE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; SEQUENCE SPECIFIC PRIMER;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTERLEUKIN-27; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84874813762     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2013.01.015     Document Type: Article

References (29)

1. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., Wolf S.F., Gately M.K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 1993, 178:1223-1230.
2. Chae S.C., Li C.S., Kim K.M., Yang J.Y., Zhang Q., Lee Y.C., Yang Y.S., Chung H.T. Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J. Hum. Genet. 2007, 52:355-361.
3. Chisari F.V. Rous-Whipple award lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am. J. Pathol. 2000, 156:1117-1132.
4. Chiyo M., Shimozato O., Yu L., Kawamura K., Iizasa T., Fujisawa T., Tagawa M. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 2005, 115:437-442.
5. Cordoba-Rodriguez R., Frucht D.M. IL-23 and IL-27: new members of the growing family of IL-12-related cytokines with important implications for therapeutics. Expert Opin. Biol. Ther. 2003, 3:715-723.
6. Dragani T.A. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol. 2010, 52:252-257.
7. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
8. Faivre S., Bouattour M., Raymond E. Novel molecular therapies in hepatocellular carcinoma. Liver Int. 2011, 31(Suppl. 1):151-160.
9. Hisada M., Kamiya S., Fujita K., Belladonna M.L., Aoki T., Koyanagi Y., Mizuguchi J., Yoshimoto T. Potent antitumor activity of interleukin-27. Cancer Res. 2004, 64:1152-1156.
10. Huang Z.Q., Wang J.L., Pan G.G., Wei Y.S. Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk. Clin. Biochem. 2012, 45:54-59.
11. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., Loudon R., Sherman F., Perussia B., Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 1989, 170:827-845.
12. Li Z., Zhang Z., He Z., Tang W., Li T., Zeng Z., He L., Shi Y. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009, 19:519-523.
13. Michielsen P.P., Francque S.M., van Dongen J.L. Viral hepatitis and hepatocellular carcinoma. World J. Surg. Oncol. 2005, 3:27.
14. Nagai H., Oniki S., Fujiwara S., Xu M., Mizoguchi I., Yoshimoto T., Nishigori C. Antitumor activities of interleukin-27 on melanoma. Endocr. Metab. Immune Disord. Drug Targets 2010, 10:41-46.
15. Nanni P., Nicoletti G., De Giovanni C., Landuzzi L., Di Carlo E., Cavallo F., Pupa S.M., Rossi I., Colombo M.P., Ricci C., Astolfi A., Musiani P., Forni G., Lollini P.L. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 2001, 194:1195-1205.
16. Noguchi Y., Jungbluth A., Richards E.C., Old L.J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl. Acad. Sci. USA 1996, 93:11798-11801.
17. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
18. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., Hibbert L., Churakova T., Travis M., Vaisberg E., Blumenschein W.M., Mattson J.D., Wagner J.L., To W., Zurawski S., McClanahan T.K., Gorman D.M., Bazan J.F., de Waal Malefyt R., Rennick D., Kastelein R.A. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
19. Shi Y.Y., He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15:97-98.
20. Shimizu M., Shimamura M., Owaki T., Asakawa M., Fujita K., Kudo M., Iwakura Y., Takeda Y., Luster A.D., Mizuguchi J., Yoshimoto T. Antiangiogenic and antitumor activities of IL-27. J. Immunol. 2006, 176:7317-7324.
21. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68:978-989.
22. Stern A.S., Podlaski F.J., Hulmes J.D., Pan Y.C., Quinn P.M., Wolitzky A.G., Familletti P.C., Stremlo D.L., Truitt T., Chizzonite R., et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 1990, 87:6808-6812.
23. Tao Y.P., Wang W.L., Li S.Y., Zhang J., Shi Q.Z., Zhao F., Zhao B.S. Associations between polymorphisms in IL-12A, IL-12B, IL-12Rbeta1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer. J. Cancer Res. Clin. Oncol. 2012, 138:1891-1900.
24. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
25. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
26. Wang B., Huang G., Wang D., Li A., Xu Z., Dong R., Zhang D., Zhou W. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J. Hepatol. 2010, 53:508-518.
27. Wei Y.S., Lan Y., Luo B., Lu D., Nong H.B. Association of variants in the interleukin-27 and interleukin-12 gene with nasopharyngeal carcinoma. Mol. Carcinog. 2009, 48:751-757.
28. Wolf S.F., Sieburth D., Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells 1994, 12:154-168.
29. Zhan Y.Z., Jiang L.P., Wang L., Xie Y.Y., Zhu C.M., Guo S.L. A association between interleukin 27 gene polymorphisms and susceptibility to tuberculosis. J. Fourth Mil. Med. Univ. 2009, 30:3100-3103.